Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet. 2005;366(9493):1267-78. https://doi.org/10.1016/S0140-6736(05)67394-1

Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England J Med. 2008;359(21):2195–207. https://doi.org/10.1056/NEJMoa0807646.

Article  CAS  Google Scholar 

Freeman DJ, Norrie J, Sattar N, Neely RDG, Cobbe SM, Ford I, et al. Pravastatin and the Development of Diabetes Mellitus. Circulation. 2001;103(3):357–62. https://doi.org/10.1161/01.CIR.103.3.357.

Article  PubMed  CAS  Google Scholar 

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42. https://doi.org/10.1016/S0140-6736(09)61965-6.

Article  PubMed  CAS  Google Scholar 

Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women’s Health Initiative. Arch Int Med. 2012;172(2):144–52. https://doi.org/10.1001/archinternmed.2011.625.

Article  Google Scholar 

Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis. JAMA. 2011;305(24):2556–64. https://doi.org/10.1001/jama.2011.860.

Article  PubMed  CAS  Google Scholar 

Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. Am J Cardiol. 2013;111(8):1123–30. https://doi.org/10.1016/j.amjcard.2012.12.037.

Article  PubMed  CAS  Google Scholar 

Reith C, Preiss D, Blackwell L, Emberson J, Spata E, Davies K, et al. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diab Endocrinol. 2024;12(5):306–19. https://doi.org/10.1016/S2213-8587(24)00040-8.

Article  Google Scholar 

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England J Med. 2015;372(25):2387–97. https://doi.org/10.1056/NEJMoa1410489.

Article  CAS  Google Scholar 

Shah NP, McGuire DK, Cannon CP, Giugliano RP, Lokhnygina Y, Page CB, et al. Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT. J Am Heart Assoc. 2023;12(13): e029593.

Article  PubMed  PubMed Central  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England J Med. 2017;376(18):1713–22. https://doi.org/10.1056/NEJMoa1615664.

Article  CAS  Google Scholar 

Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diab Endocrinol. 2017;5(12):941–50. https://doi.org/10.1016/S2213-8587(17)30313-3.

Article  CAS  Google Scholar 

Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, et al. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diab Obes Metabol. 2024;26(8):3223–37. https://doi.org/10.1111/dom.15650.

Article  CAS  Google Scholar 

Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New England J Med. 2023;388(15):1353–64. https://doi.org/10.1056/NEJMoa2215024.

Article  Google Scholar 

Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, Nissen SE. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diab Endocrinol. 2024;12(1):19–28.

Article  CAS  Google Scholar 

Alvarez-Jimenez L, Morales-Palomo F, Moreno-Cabañas A, Ortega JF, Mora-Rodríguez R. Effects of statin therapy on glycemic control and insulin resistance: A systematic review and meta-analysis. Eur J Pharmacol. 2023;947: 175672.

Article  PubMed  CAS  Google Scholar 

Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351–61.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian Randomization Study of <i>ACLY</i> and Cardiovascular Disease. New England J Med. 2019;380(11):1033–42. https://doi.org/10.1056/NEJMoa1806747.

Article  CAS  Google Scholar 

Abbasi F, Lamendola C, Harris CS, Harris V, Tsai M-S, Tripathi P, et al. Statins Are Associated With Increased Insulin Resistance and Secretion. Arteriosclerosis, Thrombosis Vasc Biol. 2021;41(11):2786–97. https://doi.org/10.1161/ATVBAHA.121.316159.

Article  CAS  Google Scholar 

Brown MS, Goldstein JL. Sterol Regulatory Element Binding Proteins (Srebps): Controllers of Lipid Synthesis and Cellular Uptake. Nutri Rev. 1998;56:S1–3. https://doi.org/10.1111/j.1753-4887.1998.tb01680.x.

Article  CAS  Google Scholar 

Brown MS, Goldstein JL. The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor. Cell. 1997;89(3):331–40. https://doi.org/10.1016/S0092-8674(00)80213-5.

Article  PubMed  CAS  Google Scholar 

Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125–31.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Knebel B, Haas J, Hartwig S, Jacob S, Köllmer C, Nitzgen U, et al. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PloS One. 2012;7(2): e31812.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang X, Huang R, Zhang L, Li S, Luo J, Gu Y, et al. A severe atherosclerosis mouse model on the resistant NOD background. Disease Models & Mechanisms. 2018;11(10). https://doi.org/10.1242/dmm.033852.

Metz S, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem J. 1993;295(1):31–40.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet β-cells. Br J Pharm. 1999;126(5):1205–13.

Article  CAS  Google Scholar 

Ishikawa M, Okajima F, Inoue N, Motomura K, Kato T, Takahashi A, et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a β-cell line, MIN6 cells. J Atherosclerosis Thrombosis. 2006;13(6):329–35.

Article  CAS  Google Scholar 

Lorza-Gil E, Salerno AG, Wanschel AC, Vettorazzi JF, Ferreira MS, Rentz T, et al. Chronic use of pravastatin reduces insulin exocytosis and increases β-cell death in hypercholesterolemic mice. Toxicology. 2016;344:42–52.

Article  PubMed  Google Scholar 

Shen L, Gu Y, Qiu Y, Cheng T, Nie A, Cui C, et al. Atorvastatin Targets the Islet Mevalonate Pathway to Dysregulate mTOR Signaling and Reduce β-Cell Functional Mass. Diabetes. 2019;69(1):48–59. https://doi.org/10.2337/db19-0178.

Article  PubMed  CAS  Google Scholar 

Takei S, Nagashima S, Takei A, Yamamuro D, Wakabayashi T, Murakami A, et al. β-Cell–Specific Deletion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) Reductase Causes Overt Diabetes due to Reduction of β-Cell Mass and Impaired Insulin Secretion. Diabetes. 2020;69(11):2352–63. https://doi.org/10.2337/db19-0996.

Article  PubMed  CAS  Google Scholar 

Mbikay M, Sirois F, Mayne J, Wang G-S, Chen A, Dewpura T, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS letters. 2010;584(4):701–6.

Article  PubMed  CAS